Indeed, TKIs used in lung cancer own anti-EGFR activity (gefitinib and erlotinib), while TKIs used in RCCs have mainly anti-vascular endothelial growth factor (VEGF) properties (sunitinib, sorafenib, axitinib and pazopanib). This evidence concerns the gene VEGFA and lung cancer.